An epigenetic modifier triggers therapeutic immune responses against breast cancer

An epigenetic modifier triggers therapeutic immune responses against breast cancer

Bibliographic Details
Main Authors:	Lorenzo Galluzzi, Guido Kroemer
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-05-01
Series:	OncoImmunology
Subjects:	cd8+ cytotoxic t cells chemotherapy immune checkpoint blockade pd-1 tmp195 tumor-associated macrophages
Online Access:	http://dx.doi.org/10.1080/2162402X.2017.1313376

Similar Items

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
by: Eric Bartee, et al.
Published: (2017-05-01)

Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression
by: Hayana Ramos Lima, et al.
Published: (2017-12-01)

Immune Checkpoint Molecules and Cancer Immunotherapy
Published: (2019)

Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives
by: Qingle Song, et al.
Published: (2021-10-01)

Cervical Cancer: Emerging Immune Landscape and Treatment
by: Guo L, et al.
Published: (2020-08-01)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
by: Jan Willem Kleinovink, et al.
Published: (2017-07-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

CD103+ cells at the forefront of anticancer immunity
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)

Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
by: Emelie Rådestad, et al.
Published: (2019-02-01)

Crizotinib – a tyrosine kinase inhibitor that stimulates immunogenic cell death
by: Peng Liu, et al.
Published: (2019-07-01)

The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection
by: Kristen E. Pauken, et al.
Published: (2020-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
by: Maria Georganaki, et al.
Published: (2018-12-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Trial Watch: Adoptively transferred cells for anticancer immunotherapy
by: Carole Fournier, et al.
Published: (2017-11-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
by: Zachary S. Buchwald, et al.
Published: (2018-12-01)

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial
by: Anne Gomez-Brouchet, et al.
Published: (2017-09-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

Targeting adenosine for cancer immunotherapy
by: Robert D. Leone, et al.
Published: (2018-06-01)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
by: Shuguang Tan, et al.
Published: (2016-11-01)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
by: Anja Wessely, et al.
Published: (2020-01-01)

Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination
by: Pierre Tannig, et al.
Published: (2020-10-01)

The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
by: Chung-Pu Wu, et al.
Published: (2019-12-01)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
by: Giandomenico Roviello, et al.
Published: (2021-08-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
by: Jan Willem Kleinovink, et al.
Published: (2017-04-01)

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
by: William Damsky, et al.
Published: (2019-06-01)

Harnessing tumor-associated macrophages as aids for cancer immunotherapy
by: Xiaolei Li, et al.
Published: (2019-12-01)

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
by: Cinzia Solinas, et al.
Published: (2021-04-01)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
by: Jinah Yeo, et al.
Published: (2021-02-01)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
by: Junyu Long, et al.
Published: (2017-08-01)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
by: Siddh van Oost, et al.
Published: (2021-08-01)

Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
by: Stephanie Dorta-Estremera, et al.
Published: (2019-09-01)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
by: Ana Bocanegra, et al.
Published: (2019-04-01)

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
by: Li Li, et al.
Published: (2021-01-01)

Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
by: Zhiwu Tan, et al.
Published: (2021-03-01)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
by: Julie Vackova, et al.
Published: (2021-04-01)

Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis
by: Oliver Kepp, et al.
Published: (2020-01-01)

Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs
by: Stanislav Pantelyushin, et al.
Published: (2021-02-01)

Overcoming Immune Evasion in Melanoma
by: Kevinn Eddy, et al.
Published: (2020-11-01)